Drug

Ranibizumab clinical trials

Also written RFB002.

studies test it: 351
open now: 5
in phase 3: 88
first study started: 2000

How each study uses Ranibizumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Ranibizumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States: 30 Jun 2006 · LUCENTIS · BLA 125156 (FDA, Drugs@FDA)
European Union: 22 Jan 2007 · Lucentis · EMEA/H/C/000715 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Ranibizumab: 215
Lucentis: 187
Ranibizumab 0.5 mg: 14
Ranibizumab (Lucentis): 10
Ranibizumab 0.5mg: 9

Development codes

RFB002: 4
CMAB818: 1
QL1205: 1
rhuFab: 1
PF582: 1
DIN 02296810: 1
RO4893594: 1

Biosimilars

Ranibizumab-eqrn: 1

Studies by the year they started

350 studies that test it; most in 2007 (38)

Studies that test Ranibizumab, by start year
Year	Studies
2000	1
2002	1
2003	3
2004	5
2005	8
2006	18
2007	38
2008	36
2009	24
2010	32
2011	28
2012	19
2013	27
2014	25
2015	24
2016	13
2017	10
2018	4
2019	4
2020	6
2021	10
2022	3
2023	3
2024	4
2025	2
2026	2

By phase

A phase 1/2 study counts in both.

Early Phase 1: 1
Phase 1: 78
Phase 2: 115
Phase 3: 88
Phase 4: 84
No phase: 34

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Macular Degeneration: 73
Retinal Vein Occlusion: 29
Macular Edema: 27
Diabetic Retinopathy: 23
Choroidal Neovascularization: 23
Polypoidal Choroidal Vasculopathy: 8
Retinopathy of Prematurity: 6
Vision Disorders: 6
Uveal Melanoma: 6
Wet Macular Degeneration: 5
Glaucoma: 5
Edema: 5

Who runs them

Industry 108 · Other 243

Novartis Pharmaceuticals (43) · Genentech, Inc. (17) · Novartis (11) · Hoffmann-La Roche (7) · National Eye Institute (NEI) (6) · California Retina Consultants (6) · Vitreous -Retina- Macula Consultants of New York (6) · University of Miami (5)

Often tested with

Tested in the same studies.

Bevacizumab (15) · Aflibercept (14) · Dexamethasone (9) · Verteporfin (7) · Dexamethasone Intravitreal Implant (4) · Photodynamic Therapy (4) · DRUG 601 (2) · LKA651 (2)

Related medicines

As reviewed, each with the page that says it.

One of Angiogenesis inhibitors source

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 8 phase 3 studies under way

Ranibizumab is the comparator. A study of two new drugs counts under both.

2Remigromig · EyeBiotech Ltd. · next primary completion Jan 2027
1OLN324 · Ollin Biosciences, Inc. · next primary completion Dec 2028
1BAT5906 · Bio-Thera Solutions · next primary completion Apr 2027

Reaching primary completion within a year · 3, 2 in phase 3

Studies that test Ranibizumab, phase 3 first.

Feb 2027A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)Phase 3 · Hoffmann-La Roche
Jun 2027A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)Phase 3 · Hoffmann-La Roche
Jul 2027A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)Phase 4 · Genentech, Inc.

Studies

Open first, then newest update. How each study uses Ranibizumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 351

See all 351 studies that test Ranibizumab →

Given beside what is tested · 60 — Ranibizumab is usual care or a partner of the new treatment

Showing 20 of 60.

As the comparator · 61 — what is tested is compared with Ranibizumab

Showing 20 of 61.

What changed recently

From the registry's own updates since Oct 15, 2026.

Newly registered1

Macular Vascular Density After Aflibercept or Ranibizumab Treatment for Diabetic Macular EdemaNov 9, 2026NCT07924072

Codes

What other systems call Ranibizumab · ClinicalTrials.gg INT006612

MeSH (NLM) D000069579RanibizumabConfirmed ClinicalTrials.gov, NLM, Wikidata
UNII (FDA) ZL1R02VT79RANIBIZUMABConfirmed FDA, NLM, Wikidata
RxNorm 595060Confirmed FDA, Wikidata
Wikidata Q414270ranibizumabConfirmed FDA, NLM, Wikidata
NCI Thesaurus C67562RanibizumabOne source FDA
DrugBank DB01270One source Wikidata

System	Code	Name there	Checked by
MeSH (NLM)	D000069579	Ranibizumab	Confirmed ClinicalTrials.gov, NLM, Wikidata
UNII (FDA)	ZL1R02VT79	RANIBIZUMAB	Confirmed FDA, NLM, Wikidata
RxNorm	595060	—	Confirmed FDA, Wikidata
Wikidata	Q414270	ranibizumab	Confirmed FDA, NLM, Wikidata
NCI Thesaurus	C67562	Ranibizumab	One source FDA
DrugBank	DB01270	—	One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.